| Literature DB >> 36061393 |
Luo-Na Lin1, Jin-Si Zhou1, Chun-Zhen Hua1, Guan-Nan Bai1, Yu-Mei Mi1, Ming-Ming Zhou2.
Abstract
Background: Despite the expanded immunization programs, the "re-emergence of pertussis" has become a global concern in recent years. At present, the prevalence of pertussis in China is seriously underestimated, and the role of close contact on the disease spreading in children remains unclear.Entities:
Keywords: Bordetella pertussis; antibiotic resistance; bacteria culture; children; close contacts
Year: 2022 PMID: 36061393 PMCID: PMC9434343 DOI: 10.3389/fped.2022.976796
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Distribution of nasopharyngeal swabs culture results for B. pertussis in 350 index cases and their household close contacts.
| Household close contacts structure | Household close contacts | Index cases | |
|
| |||
| Positive | 116 | 73 | 43 |
| Mother | 67 | 43 | 24 |
| Father | 17 | 11 | 6 |
| Grandfather | 4 | 2 | 2 |
| Grandmother | 18 | 13 | 5 |
| Sibling | 8 | 4 | 4 |
| Baby-sitter | 2 | 0 | 2 |
| Negative | 830 | 302 | 528 |
| Mother | 283 | 87 | 196 |
| Father | 333 | 119 | 214 |
| Grandfather | 60 | 16 | 44 |
| Grandmother | 97 | 47 | 50 |
| Sibling | 51 | 27 | 24 |
| Baby-sitter | 6 | 0 | 6 |
FIGURE 1The yearly distribution of children and close contacts between 2018 and 2020.
FIGURE 2The distribution of pertussis cases (A) and positive household close-contacts (B) between 2018 and 2020.
Vaccination and antibiotic therapy status and clinical outcome of pertussis cases and pertussis-like cases.
| Pertussis cases | Pertussis-like cases | χ 2/Z |
| ||
|
| |||||
| Unvaccinated | 45 (26.9) | 77 (42.1) | 8.803 | 0.003 | |
| Vaccinated1-2doses | 30 (18.0) | 40 (21.9) | 0.827 | 0.363 | |
| Vaccinated ≥ 3 doses | 11 (6.6) | 9 (4.9) | 0.451 | 0.502 | |
| Unknown | 3 (1.8) | 2 (1.1) | 0.673 | 0.457 | |
| Delayed vaccination | 32 (19.2) | 44 (24.0) | 0.998 | 0.318 | |
|
| |||||
| Yes | 158 (94.5) | 173 (94.5) | 0.001 | 0.975 | |
| Macrolides | |||||
| Cases | 69 (41.3) | 70 (38.3) | 0.343 | 0.558 | |
| Course (days) | Median (IQR) | 4 (2.5,7) | 4 (2,6) | –0.202 | 0.894 |
|
| |||||
| Cases | 10 (6.0) | 9 (4.2) | 0.195 | 0.659 | |
| Course (days) | Median (IQR) | 3 (1,5.25) | 4 (2,6) | –0.788 | 0.447 |
| Macrolides and β-lactams | |||||
| Cases | 66 (39.5) | 70 (38.3) | 0.059 | 0.808 | |
| Course (days) | Median (IQR) | 8 (5,12) | 12 (7,15) | –2.837 | 0.04 |
| Others | 13 (7.8) | 24 (13.1) | 2.624 | 0.105 | |
|
| – | – | |||
| Hospitalization | 89 (53.3) | 125 (66.8) | 8.283 | 0.004 | |
| Length of stay | Median (IQR) | 14 (13,17) | 9 (7,13) | –6.949 | 0.00 |
aUnknown refer to data loss due to the unavailability of information.
bOthers refer to antibiotics other than macrolides and β-lactams.
cAmong 167 pertussis cases, 89 were younger than 6 months old and all were inpatients. Of the 183 pertussis-like cases, 179 were hospitalized, and 125 were hospitalized in patients younger than 6 months of age.
Differences in age, gender and family-related factors across subgroups (n = 350).
| Characters | Child (–)/close contacts (–) | Child (–)/close contacts (+) | Child (+)/close contacts (–) | Child (+)/close contacts (+) | ||
| Age | 0.011 | |||||
| 0–3 months | 57 (31.1%) | 7 (18.9%) | 13 (19.4%) | 17 (27.0%) | ||
| 3–6 months | 71 (38.8%) | 8 (21.6%) | 21 (31.3%) | 24 (38.1%) | ||
| > 6 months | 55 (30.1%) | 22 (59.5%) | 33 (49.3%) | 22 (34.9%) | ||
| Gender | 0.777 | |||||
| Male | 100 (54.6%) | 17 (45.9%) | 37 (55.2%) | 35 (55.6%) | ||
| Female | 83 (45.4%) | 20 (54.1%) | 30 (44.8%) | 28 (44.4%) | ||
| Multiple children | 0.078 | |||||
| No | 160 (87.4%) | 32 (86.5%) | 53 (79.1%) | 47 (74.6%) | ||
| Yes | 23 (12.6%) | 5 (13.5%) | 14 (20.9%) | 16 (25.4%) | ||
| Other female caregivers in the household except for mother | <0.001 | |||||
| No | 143 (78.1%) | 21 (56.8%) | 41 (61.2%) | 30 (47.6%) | ||
| Yes | 40 (21.9%) | 16 (43.2%) | 26 (38.8%) | 33 (52.4%) | ||
| Number of family members in the household | <0.001 | |||||
| Three | 122 (66.7%) | 19 (51.4%) | 30 (44.8%) | 22 (34.9%) | ||
| Four or more | 61 (33.3%) | 18 (48.6%) | 37 (55.2%) | 41 (65.1%) |
MICs of 9 antimicrobial agents against 130 B. pertussis strains isolated from index cases.
| Antibiotics | MIC range | MIC50 | MIC90 |
| Erythromycin | 0.047– > 256 | >256 | >256 |
| Azithromycin | 0.016– > 256 | >256 | >256 |
| Clindamycin | 0.023– > 256 | >256 | >256 |
| SXT | 0.016–1.000 | 0.190 | 0.50 |
| Ampicillin | 0.032–0.500 | 0.125 | 0.25 |
| Piperacillin | <0.016–0.094 | <0.016 | <0.016 |
| Ceftriaxone | 0.008–0.125 | 0.064 | 0.094 |
| Ceftazidime | 0.023–1.000 | 0.940 | 0.19 |
| Meropenem | 0.006–0.125 | 0.047 | 0.125 |
MIC, minimum inhibitory concentration; SXT, Trimethoprim-sulfamethoxazole.
aMIC50, MIC at which 50% of the isolates tested are inhibited.
bMIC90, MIC at which 90% of the isolates tested are inhibited.
The clearance rate of B. pertussis in treatment with different antibiotics.
| Antibiotics | Cases ( | Clearance rate in nasopharynx% ( | |
|
| |||
| 1 week into treatment | 2 weeks into treatment | ||
| Macrolides | 12 | 41.7 (5/12) | 75.0 (9/12) |
| Cefoperazone-sulbactam | 18 | 66.7 (12/18) | 94.4 (17/18) |
| Piperacillin-tazobactam | 2 | 50.0 (1/2) | 50.0 (1/2) |
| Cefoperazone-sulbactam instead of macrolides with poor efficacy | 64 | 59.4 (38/64) | 92.2 (59/64) |
| Piperacillin-tazobactam instead of macrolides with poor efficacy | 14 | 71.4 (10/14) | 92.9 (13/14) |
| Others | 20 | 25.0 (5/20) | 80.0 (16/20) |
| Total | 130 | 54.6 (71/130) | 88.5 (115/130) |
aBesides antibiotics in hospitalization, ambulatory treatment was included when the same antibiotic was continued after admission.
bSeven with erythromycin, five with azithromycin.
cIf the symptom did not improve after 7-day of macrolides for therapy (included ambulatory treatment followed by hospitalization treatment of the same antibiotic), it would be considered as poor efficacy or inefficacy, and cefoperazone-sulbactam or piperacillin-tazobactam would be prescribed instead.